Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Sanofi SA — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.91, while Sanofi SA trades at $44.11 (market cap $103.94B). The key difference: Sanofi SA pays a 5.54% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| FNGU | SNY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $52.34 |
52-Week Low | $13.73 | $41.33 |
Market Cap | — | $103.94B |
Enterprise Value | — | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $28.77, down 0.45% on the day. The technical picture is mixed, with moving averages signaling bullish momentum but oscillators and a high RSI indicating overbought conditions. Recent news highlights the extreme volatility and decay inherent to its leveraged structure, with one report noting a $10,000 position losing 16% in a single session in June 2026.
The outlook is dominated by the product's high-risk, tactical nature. The opportunity lies in capturing amplified gains during strong bullish trends in mega-cap tech. The primary risk is significant capital erosion during volatile or sideways markets due to daily resetting leverage and compounding costs, making it unsuitable for long-term holding.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
